← Browse by Condition
Medical Condition

epithelial ovarian cancer

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 1

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — epithelial ovarian cancer Clinical Trials

How many clinical trials are currently recruiting for epithelial ovarian cancer?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for epithelial ovarian cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for epithelial ovarian cancer?
epithelial ovarian cancer research spans Phase 1 (2 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a epithelial ovarian cancer clinical trial?
Eligibility criteria for epithelial ovarian cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Phase 3
1
Top Sponsors
Memorial Sloan Kettering Cancer Center 1 trial
Radboud University Medical Center 1 trial
Case Comprehensive Cancer Center 1 trial
Japanese Gynecologic Oncology Group 1 trial
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 1 trial

Recruiting Clinical Trials

NCT05429970
Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Enrollment
35 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05773859 Phase 1, Phase 2
Recruiting

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Enrollment
10 pts
Location
Netherlands
Sponsor
Radboud University Medical Cen...
View Trial →
NCT06386887
Recruiting

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Enrollment
20 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
View Trial →
NCT04063527 Phase 3
Recruiting

Phase III Trial of Stage I Ovarian Cancer After Surgery

Enrollment
360 pts
Location
Japan, South Korea
Sponsor
Japanese Gynecologic Oncology ...
View Trial →
NCT04516447 Phase 1
Recruiting

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Enrollment
172 pts
Location
United States, Austr...
Sponsor
K-Group, Beta, Inc., a wholly ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology